Clinical Neuroscience

[Report]

HORÁNYI Béla1

DECEMBER 01, 1959

Clinical Neuroscience - 1959;12(12)

[The author reports on the symposium held in Jena, Germany, October 17-19, 1959, by the Electroencephalography Society of Democratic Germany.]

AFFILIATIONS

  1. Egyetemi Tanár

COMMENTS

0 comments

Further articles in this publication

Clinical Neuroscience

Hyperkinese und Motilitätspsychose

KARL Leonhard

Die Hyperkinese, d. h. rein im Psychomotorischen ablaufende Erregung, gibt noch keinen Hinweis auf eine Katatonie. Wenn es sich um eine einfache Vermehrung der Reaktiv- und Ausdrucksbewegungen handelt, dann ist im Gegenteil eine heilbare Motilitätspsychose anzunehmen. Erst, wenn Verzerrungen im Bewegungsablauf erkennbar werden, ist die Diagnose und Prognose im Sinne der Katatonie zu stellen. In akinetischen Zustenden weisen Verzerrungen der Haltung oder negativitische Züge darauf hin, dass nicht die heilbare akinetische Motilitätspsychose, sondern eine akinetische Katatonie vorliegt. Von der periodischen Katatonie sind fernehin die systematischen Formen von Katatonie mit ihren charakterischen Bildern und einem schleichenden Verlauf zu trennen.

Clinical Neuroscience

[Clinical and pathological data on poiloencephalitis haemorrhagica superior]

JUHÁSZ Pál, SÉRA Ibolya

[Our 43-year-old patient presented with two well-known pathologies, spinal demyelination and polioencephalitis haemorrhagica superior, due to deficiency disease and toxic damage. The co-occurrence of the two is unknown in the literature. From the clinical picture, it appears that polyoencephalopathic reactio is a relatively late complication of spinal demyelinopathy. ]

Clinical Neuroscience

[Cerebral venous pressure testing in humans ]

SOLTI Ferenc, SIMONYI Gusztáv, RÉV Judit, HERMANN Róbert, PÉTER Ágnes, ISKUM Miklós

[Cerebral venous pressure was measured regularly by puncture of the internal jugular vein. 1. Cerebral venous pressure varied within wide limits (19-164 mmW). 2. There was no parallel between the cerebral venous pressure and the cubital venous pressure, and the two venous systems usually behaved differently on inspiration. 3. No correlation was found between CSF pressure magnitude and cerebral venous pressure magnitude. Similarly, there was no correlation between CSF pressure and venous cubital pressure. 4 Our experiments suggest that the determination of cerebral venous pressure is necessary for experimental studies of cerebral circulation.]

Clinical Neuroscience

[Neurological complications of malignant haematopoietic disorders]

AMBRÓZY György, ECKHARDT Sándor, GALLAI Margit

[1.In 6.2% (19 cases) of 306 malignant haematological malignancies we observed neurological complications, 11 patients had radiculomedullary syndrome, 3 patients had disturbed consciousness, 5 patients had lesions of the cranial nerves and one patient had lesions of the sympathetic nervous system. 2. In seven cases, neurological symptoms were the initial complaint of the patient. In order to diagnose the pathology early, we call attention to histological examination of lymph nodes, skeletal radiography, serum and CSF electrophoresis, peripheral blood count, bone marrow aspirate if necessary. 3. Radiotherapy for local neurological lesions ; combined cytostatic and radiotherapy for generalised tumours or advanced leukaemias ; surgical treatment for severe spinal cord compression. ]

Clinical Neuroscience

[Data on the mechanism of generation of cortical spasm potentials]

FEHÉR Ottó, HALÁSZ Péter, MECHLER Ferenc

[Authors have induced seizure potentials in cat cerebral cortex by the combined use of strychnine, d-tubocurarine, and one of these agents and an eserine acetylcholine solution. The neuronal substrates of these spasm potentials were studied by surface and deep macroelectrode and microelectrode ablation. It was found that strychnine and d-tubocurarine potentials are also generated in the sleeping cortex and are not accompanied by single-cell activity. The latter is only associated with a mainly first, positive phase of these potentials in awake cortex. Eserine acetylcholine induces a rhythmic afterglow in the cortex treated with the two former agents, which is no longer localised to the upper 5-600 Y of the cortex but is detected throughout the entire depth of the cortex. Single-cell discharges are then observed in precise correlation with all surface waves. There is no rhythmic afterdischarge without single-cell activity. Authors conclude that the neuronal substrate of rhythmic aftershocks, which is very similar to the epileptic electrogram, is a vertical excitatory circuit within the cortex, in which the excitation moves from the surface to the deep and then switches back to the surface. This circuit, which also sends impulses to other brain areas and the periphery of the body, can be interrupted by the use of atropine and diphedan. The type of discharge described above is considered by the authors to be a model of discharge during an epileptic seizure, which seems to be suitable for testing antiepileptic effects. ]

All articles in the issue

Related contents

Clinical Neuroscience

Late simultaneous carcinomatous meningitis, temporal bone infiltrating macro-metastasis and disseminated multi-organ micro-metastases presenting with mono-symptomatic vertigo – a clinico-pathological case reporT

JARABIN András János, KLIVÉNYI Péter, TISZLAVICZ László, MOLNÁR Anna Fiona, GION Katalin, FÖLDESI Imre, KISS Geza Jozsef, ROVÓ László, BELLA Zsolt

Although vertigo is one of the most common complaints, intracranial malignant tumors rarely cause sudden asymmetry between the tone of the vestibular peripheries masquerading as a peripheral-like disorder. Here we report a case of simultaneous temporal bone infiltrating macro-metastasis and disseminated multi-organ micro-metastases presenting as acute unilateral vestibular syndrome, due to the reawakening of a primary gastric signet ring cell carcinoma. Purpose – Our objective was to identify those pathophysiological steps that may explain the complex process of tumor reawakening, dissemination. The possible causes of vestibular asymmetry were also traced. A 56-year-old male patient’s interdisciplinary medical data had been retrospectively analyzed. Original clinical and pathological results have been collected and thoroughly reevaluated, then new histological staining and immunohistochemistry methods have been added to the diagnostic pool. During the autopsy the cerebrum and cerebellum was edematous. The apex of the left petrous bone was infiltrated and destructed by a tumor mass of 2x2 cm in size. Histological reexamination of the original gastric resection specimen slides revealed focal submucosal tumorous infiltration with a vascular invasion. By immunohistochemistry mainly single infiltrating tumor cells were observed with Cytokeratin 7 and Vimentin positivity and partial loss of E-cadherin staining. The subsequent histological examination of necropsy tissue specimens confirmed the disseminated, multi-organ microscopic tumorous invasion. Discussion – It has been recently reported that the expression of Vimentin and the loss of E-cadherin is significantly associated with advanced stage, lymph node metastasis, vascular and neural invasion and undifferentiated type with p<0.05 significance. As our patient was middle aged and had no immune-deficiency, the promoting factor of the reawakening of the primary GC malignant disease after a 9-year-long period of dormancy remained undiscovered. The organ-specific tropism explained by the “seed and soil” theory was unexpected, due to rare occurrence of gastric cancer to metastasize in the meninges given that only a minority of these cells would be capable of crossing the blood brain barrier. Patients with past malignancies and new onset of neurological symptoms should alert the physician to central nervous system involvement, and the appropriate, targeted diagnostic and therapeutic work-up should be established immediately. Targeted staining with specific antibodies is recommended. Recent studies on cell lines indicate that metformin strongly inhibits epithelial-mesenchymal transition of gastric cancer cells. Therefore, further studies need to be performed on cases positive for epithelial-mesenchymal transition.

Clinical Neuroscience

Atypical presentation of late-onset Sandhoff disease: a case report

SALAMON András , SZPISJAK László , ZÁDORI Dénes, LÉNÁRT István, MARÓTI Zoltán, KALMÁR Tibor , BRIERLEY M. H. Charlotte, DEEGAN B. Patrick , KLIVÉNYI Péter

Sandhoff disease is a rare type of hereditary (autosomal recessive) GM2-gangliosidosis, which is caused by mutation of the HEXB gene. Disruption of the β subunit of the hexosaminidase (Hex) enzyme affects the function of both the Hex-A and Hex-B isoforms. The severity and the age of onset of the disease (infantile or classic; juvenile; adult) depends on the residual activity of the enzyme. The late-onset form is characterized by diverse symptomatology, comprising motor neuron disease, ataxia, tremor, dystonia, psychiatric symptoms and neuropathy. A 36-year-old female patient has been presenting progressive, symmetrical lower limb weakness for 9 years. Detailed neurological examination revealed mild symmetrical weakness in the hip flexors without the involvement of other muscle groups. The patellar reflex was decreased on both sides. Laboratory tests showed no relevant alteration and routine electroencephalography and brain MRI were normal. Nerve conduction studies and electromyography revealed alterations corresponding to sensory neuropathy. Muscle biopsy demonstrated signs of mild neurogenic lesion. Her younger brother (32-year-old) was observed with similar symptoms. Detailed genetic study detected a known pathogenic missense mutation and a 15,088 base pair long known pathogenic deletion in the HEXB gene (NM_000521.4:c.1417G>A; NM_000521:c.-376-5836_669+1473del; double heterozygous state). Segregation analysis and hexosaminidase enzyme assay of the family further confirmed the diagnosis of late-onset Sandhoff disease. The purpose of this case report is to draw attention to the significance of late-onset Sandhoff disease amongst disorders presenting with proximal predominant symmetric lower limb muscle weakness in adulthood.

Clinical Neuroscience

A variant of Guillain-Barre syndrome after SARS-CoV-2 vaccination: AMSAN

TUTAR Kaya Nurhan, EYIGÜRBÜZ Tuğba, YILDIRIM Zerrin, KALE Nilufer

Introduction - Coronavirus disease 2019 (COVID-19) is a respiratory infection that has rapidly become a global pandemic and vaccines against SARS-CoV-2 have been developed with great success. In this article, we would like to present a patient who developed Guillain-Barré syndrome (GBS), which is a serious complication after receiving the inactive SARS-CoV-2 vaccine (CoronaVac). Case report – A 76-year-old male patient presented to the emergency department with nine days of progressive limb weakness. Two weeks prior to admission, he received the second dose of CoronaVac vaccine. Motor examination revealed decreased extremity strength with 3/5 in the lower extremities versus 4/5 in the upper extremities. Deep tendon reflexes were absent in all four extremities. Nerve conduction studies showed predominantly reduced amplitude in both motor and sensory nerves, consistent with AMSAN (acute motor and sensory axonal neuropathy). Conclusion - Clinicians should be aware of the neuro­logical complications or other side effects associated with COVID-19 vaccination so that early treatment can be an option.

Clinical Neuroscience

Acute transverse myelitis after inactivated COVID-19 vaccine

ERDEM Şimşek Nazan, DEMIRCI Seden, ÖZEL Tuğba , MAMADOVA Khalida, KARAALI Kamil , ÇELIK Tuğba Havva , USLU Ilgen Ferda, ÖZKAYNAK Sibel Sehür

Vaccines against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been rapidly developed to prevent coronavirus disease 2019 (COVID-19) pandemic. There is increasing safety concerns regarding COVID-19 vaccines. We report a 78-year old woman who was presented with tetraparesis, paresthesias of bilateral upper extremities, and urinary retention of one-day duration. Three weeks before these symptoms, she was vaccinated with CoronaVAC vaccine (Sinovac Life Sciences, China). Spine magnetic resonance imaging showed longitudinally extensive transverse myelitis (TM) from the C1 to the T3 spinal cord segment. An extensive diagnostic workup was performed to exclude other possible causes of TM. We suggest that longitudinally extensive TM may be associated with COVID-19 vaccination in this case. To the best of our knowledge, this is the first report of longitudinally extensive TM developing after CoronaVac vaccination. Clinicians should be aware of neurological symptoms after vaccination of COVID-19.

Clinical Neuroscience

[Effective therapy in highly active pediatric multiple sclerosis ]

MERÔ Gabriella, MÓSER Judit, LIPTAI Zoltán, DIÓSZEGHY Péter, BESSENYEI Mónika, CSÉPÁNY Tünde

[Multiple sclerosis (MS) is typically a disease of young adults. Childhood MS can be defined in patients under 18 years of age, although some authors set the limit un­der the age of 16 formerly known as “early-onset multiple sclerosis” or “juvenile multiple sclerosis”, seen in 3-5% of all MS patients. Nowadays, owing to ever-evolving, better diagnostic tools and well-traced, strictly defined diagnostic criteria, childhood MS is showing an increasing incidence worldwide (0.05-2.85/100 000). MS is characterized by recurrent episodes of the central nervous system with demyelination separated in space and time. In childhood almost exclusively the relapsing-remitting (RR) type of MS occurs. Based on experience in adults, the goal in the pediatric population is also the early diagnosis, to initiate adequate DMT as soon as possible and to achieve symptom relief and good quality of life. Based on efficacy and safety studies in the adult population, inter­feron β-1a and glatiramer acetate were first approved by the FDA and EMA for the treatment of childhood MS also. The increased relapse rate and rapid progression of childhood MS and unfavorable therapeutic response to nearly 45% of the first DMT necessitated the testing of more effective and second-line drugs in the population under 18 years of age (PARADIGMS, CONNECT). Although natalizumab was reported to be effective and well-tolerated in highly active RRMS in childhood, evidence based studies were not yet available when our patients’ treatment started. In this article, we report on the successful treatment of three active RRMS patients with individually authorized off-label use of natalizumab.]